Basel, Switzerland

Patrik Zueger


 

Average Co-Inventor Count = 8.0

ph-index = 1


Company Filing History:


Years Active: 2025

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovations of Patrik Zueger

Introduction

Patrik Zueger is a notable inventor based in Basel, Switzerland. He has made significant contributions to the field of pharmaceuticals, particularly through his work on rapamycin derivatives. His innovative approach has led to advancements in the treatment of various diseases and disorders.

Latest Patents

Zueger holds a patent for "Rapamycin derivatives." This patent discloses 32-deoxo-rapamycin derivatives of Formula (I), or a pharmaceutically acceptable salt thereof. It includes pharmaceutical compositions and combinations comprising a compound of Formula (I), along with methods of making these compounds. Additionally, the patent outlines methods for using a compound of Formula (I) or a pharmaceutically acceptable salt thereof for treating specific diseases and disorders.

Career Highlights

Patrik Zueger is associated with Novartis AG, a leading global healthcare company. His work at Novartis has allowed him to focus on innovative pharmaceutical solutions that address critical health challenges. His dedication to research and development has positioned him as a key figure in the industry.

Collaborations

Zueger has collaborated with esteemed colleagues, including Simone Bonazzi and Michael Connolly. These partnerships have fostered a collaborative environment that enhances the potential for groundbreaking discoveries in the pharmaceutical field.

Conclusion

Patrik Zueger's contributions to the field of pharmaceuticals, particularly through his patent on rapamycin derivatives, highlight his innovative spirit and commitment to improving healthcare. His work continues to influence the development of new treatments for various diseases.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…